Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia
- 14 June 2007
- journal article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 21 (11), 2363-2368
- https://doi.org/10.1038/sj.leu.2404807
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetBlood, 2006
- Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 yearsBlood, 2006
- Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemiaLeukemia, 2005
- Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patientsHistopathology, 2005
- Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemiaBlood, 2004